scholarly journals Cervical schwannoma with acute worsening and intratumoral hemorrhage

2021 ◽  
Vol 12 ◽  
pp. 409
Author(s):  
Uma V. Mahajan ◽  
Mohit Patel ◽  
Alia M. Hdeib
Keyword(s):  
External Beam Radiotherapy ◽  
Chronic Neck Pain ◽  
External Beam Radiation ◽  
Cervical Region ◽  
Spinal Tumors ◽  
External Beam ◽  
Beam Radiation ◽  
Intratumoral Hemorrhage ◽  
Intradural Extramedullary ◽  
Neurologically Intact

Background: Primary spinal tumors are rare and include schwannomas. In the cervical region, these lesions can cause pain, radiculopathy, and/or myelopathy. Case Description: A 53-year-old male presented with 9 months of chronic neck pain and left upper extremity radiculopathy/myelopathy. The MRI revealed an intradural extramedullary C6-C7 mass left-sided mass with foraminal extension. Following a C5-C7 laminectomy with C5-T2 instrumented fusion, the diagnosis of schwannoma with evidence of recent hemorrhage was confirmed by biopsy. Three weeks postoperatively, the patient was pain free, no longer taking opioids, and neurologically intact. Although the MR 6 months later showed no tumor, the MRI 15 months later documented a recurrent enhancing C6-C7 lesion. The patient elected to be treated with external beam radiotherapy and remained asymptomatic. Conclusion: A 53-year-old underwent resection of a cervical C6-C7 schwannoma with intratumoral hemorrhage. Fifteen months following C5-C7 laminectomy with C5-T2 fusion, the tumor recurred and required external beam radiation therapy.

Sodium Deoxyribonucleate Prevents Radiation Cystitis in Uterine or Cervical Cancer Patients

2021 ◽  
Vol 66 (5) ◽  
pp. 33-38
Author(s):  
P. Skopin ◽  
A. Ivashin ◽  
Yu. Skopina ◽  
Yu. Kozina ◽  
R. Zukov ◽  
...  
Keyword(s):  
Urine Analysis ◽  
External Beam Radiotherapy ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Postoperative Course ◽  
Radiation Cystitis ◽  
Patients With Cancer ◽  
End Of Treatment

Results: To develop a method for reducing the frequency and severity of early radiation reactions in patients with cancer of the uterus or cervix. Material and methods: We analyzed the results of treatment of 60 patients with cancer of the uterus and cervix, patients received a postoperative course of external beam radiotherapy combined with the intramuscular administration of the Derinat® radioprotector (sodium deoxyribonucleate); in the second arm, they received a postoperative course of external beam radiotherapy and standard therapy in case of radiation cystitis. The assessment of radiation reactions severity was performed with the EORTC QLQ-C30 criteria, WBC count, IPSS scale, urine analysis and cystoscopic examination evaluated with the developed by us scale. Results: Evaluation of the quality of life in patients with cervical or uterine cancer at the final stage of treatment using the IPSS scale showed that in the arm of patients with sodium deoxyribonucleate, there was a 30.4 % (p> 0.05) decrease in the symptoms of urinary disorders. The use of the radioprotector sodium deoxyribonucleate also statistically significantly reduced the incidence of radiation cystitis by 73 %. According to cystoscopy, the total bladder injury score at the end of treatment was 147 % lower. The number of leukocytes in the urine analysis at the end of treatment was 116.3 % lower (p≤0.01) in those who received sodium deoxyribonucleate Conclusion: The data obtained indicate the radioprotective efficacy of sodium deoxyribonucleate and make it possible to recommend its intramuscular administration to patients with cancer of the uterus and cervix against the background of external beam radiation therapy to reduce the frequency and severity of acute radiation cystitis in patients with cancer of the uterus or cervical cancer receiving external beam radiation therapy.

Repeat 90Y-microsphere radioembolization for hepatic malignancies: Safety and patient selection issues

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15177-15177
Author(s):  
A. S. Kennedy ◽  
W. A. Dezarn ◽  
P. McNeillie ◽  
M. England ◽  
C. Overton ◽  
...  
Keyword(s):  
Liver Function ◽  
Liver Tumors ◽  
External Beam Radiotherapy ◽  
Liver Volume ◽  
Latency Period ◽  
Normal Liver ◽  
External Beam Radiation ◽  
Unknown Primary ◽  
External Beam ◽  
Beam Radiation

15177 Background: Liver tolerance to reirradiation with multiple doses of 90Y-microspheres is not known. Many patients (pts) have also received external beam radiotherapy to the liver or through the liver and are surviving long enough to be considered for a second and third liver treatments with internal radiation. Methods: The experience of a single center treating liver tumors with resin 90Y-microspheres was used. Pts that received liver radiation prior to or after resin microsphere therapy were studied. Endpoints were toxicity, tumor response, disease type, latency period between radiation treatments, shunting to lung, and effects on liver volume and function. The delivery activity of microspheres selected was not reduced below that which was typically chosen for patients without prior liver radiation which was 25% reduced from the manufacturer’s BSA dose calculation method. All patients received bilobar microsphere delivery during a single session. Results: A total of 40 pts were identified; 14 women, 26 men, treated 6/2003 to 12/2006, with 35 pts receiving 2 courses and 5 pts with 3 courses of liver radiation. Retreatment with resin microspheres 26 pts, prior external beam radiation in 7 pts, prior glass microspheres in 2pts, prior systemic radiotherapy in 2 pts, and prior stereotactic liver radiation in 1 pt. Liver function was stable and adequate in all patients after additional liver radiation, and no pts developed radiation-induced liver dysfunction (RILD) or veno-occlusive disease (VOD). The percentage of shunting to the lung decreased with retreatment. Tumors treated: 14 carcinoid, 11 colorectal, 6 hepatocellular and cholangiocarcinoma, 2 sarcoma, 3 unknown primary, 1 each of breast, esophagus, and head and neck primaries. Conclusions: Repeated radiation to the liver with 90Y-microspheres appears safe in patients that have sufficient normal liver function and reserve based on known laboratory parameters already used for selection of microsphere therapy. No acute life-threatening, fatal, or late liver damage was observed, i.e. RILD or VOD. No specific dose reduction is recommended for retreatment of the liver. No significant financial relationships to disclose.

Stability of white blood cell counts following standard radiation approaches for high-risk adenocarcinoma of the prostate: Implications for combination therapy.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 201-201
Author(s):  
Steven E. Finkelstein ◽  
Francisco A. Myslicki ◽  
Sharon Salenius ◽  
Constantine Mantz ◽  
Neal Shore ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
High Risk ◽  
Complete Blood Count ◽  
External Beam Radiotherapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Cell Counts ◽  
Normal Ranges ◽  
Adenocarcinoma Of The Prostate

201 Background: Traditional wisdom has suggested that under some circumstances radiation therapy may be immunosuppressive, thus obviating effective combination approaches with immunotherapy. Our purpose was to test whether standard radiation therapy for high-risk prostate cancer are immune modulating, thereby prohibiting potential combination with cellular based immunotherapies such as sipuleucel-T. Methods: Retrospective analysis of complete blood count with differential (CBC) data was performed on 26 patients with high-risk adenocarcinoma of the prostate undergoing external beam radiation therapy between January 2008 and November 2010. CBC data were collected prior to radiation therapy and at up to 4 time points thereafter, and compared to normal ranges from an outside reference lab (WBC 3,800-10,700/μL; ALC 910-4,280/μL). Results: The median age was 73 (range 62-86), and 16 patients were on concurrent androgen deprivation therapy. Patients received intensity modulated, dose-escalated external beam radiotherapy. Baseline and subsequent median white blood counts (WBC) and absolute lymphocyte counts (ALC) remained within the normal ranges. In the clinically relevant time frame of <3 months following radiation therapy where sipuleucel-T could be considered, the WBC and ALC were 5,350 and 970, respectively. The median WBC and ALC then gradually increased to 5,800 and 1,250, respectively, at 6-12 months post radiation therapy. Conclusions: These data suggest that in the setting of external beam radiation approaches for high-risk adenocarcinoma of the prostate, no significant changes in either WBC or ALC were observed. The hematologic status in these patients remained stable, suggesting that combination radiation / cellular based immunotherapy approaches are feasible. Further analysis is warranted to test the potential of novel immunotherapeutic agents with radiation therapy. [Table: see text]

scholarly journals Olfactory Neuroblastoma Treated by Endoscopic Surgery Followed by Combined External Beam Radiation and Gamma Knife for Optic Nerve and Chiasm Sparing: A Case Report

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Hansi Z. Jiang ◽  
Ameer L. Elaimy ◽  
Guy C. Jones ◽  
Alexander R. Mackay ◽  
Robert K. Fairbanks ◽  
...  
Keyword(s):  
Endoscopic Surgery ◽  
External Beam Radiotherapy ◽  
Tumor Resection ◽  
Multimodality Treatment ◽  
Olfactory Neuroblastoma ◽  
Concurrent Chemotherapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
The Right

We describe the multimodality treatment regimen of a 53-year-old man diagnosed with olfactory neuroblastoma (Kadish stage C) in the right nasal cavity extending into the ethmoid sinus and across the cribriform plate. Endoscopic surgery for tumor resection was followed by a combination of external beam radiotherapy and stereotactic radiosurgery boost with concurrent chemotherapy. The novel combination of dual radiation therapies allowed for the preservation of the nearby optic structures while providing an adequate dosage to a sufficient volume of the afflicted tissue.

scholarly journals The Modern View on the Effectiveness of Cradiotherapy of Prostate Cancer

2017 ◽  
Vol 10 (3) ◽  
pp. 231-235
Author(s):  
Ivan Petrovich Moshurov ◽  
Dmitry Yuryevich Kamenev ◽  
Bronislava Borisovna Kravets ◽  
Natalia Viktorovna Korotkikh
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
External Beam Radiotherapy ◽  
External Beam Radiation ◽  
High Dose ◽  
External Beam ◽  
Beam Radiation ◽  
Results Of Treatment ◽  
Short Period

For many years the main method of treatment of patients with prostate cancer remains surgical treatment, which consists in performing a difficult and traumatic operations, leading to reduced quality of life. Currently, as an equal alternative to radical prostatectomy is radiotherapy, presented with a standard 3D conformal beam radiation, stereotactic radiotherapy and brachytherapy using sources with a low or high dose. Brachytherapy using sources of high power is a safe and effective treatment for localized prostate cancer, providing a summing fatal dose to the tumor with the short period of hospitalization, minimal complications, which may be used in combination with external beam radiotherapy and standalone version. A brief review of the literature on the use of combined radiation therapy in the treatment of prostate cancer. Describes the comparative characteristics of results of treatment of this pathology, complications, early and late toxic reactions when used brachytherapy isotopes of different dose in combination with external beam radiation therapy. The vector of further research in this direction is justified.

Combined brachytherapy and external beam radiation for prostate cancer in a community setting

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16147-e16147
Author(s):  
G. J. Kubicek ◽  
G. J. Kubicek ◽  
S. Brown ◽  
S. Redfield
Keyword(s):  
Prostate Cancer ◽  
External Beam Radiotherapy ◽  
Treatment Options ◽  
Community Setting ◽  
Late Toxicity ◽  
Biochemical Failure ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation

e16147 Background: Prostate cancer is the most common male malignancy, and there is no one standard treatment modality. One treatment option is the combination of external beam radiotherapy and permanent transperineal brachytherapy seed implant Methods: Retrospective review of prostate cancer and side effect outcomes at a single institution in the community setting. All patients were treated with a combination of low dose rate transperineal brachytherapy seed placement and external beam radiation. Results: A total of 897 patients were analyzed, 781 had a minimum follow-up of one year. Median pre-treatment PSA was 8.1 (range 0.3 to 106) and the median Gleason score was 6. With a median follow-up of 3.6 years, 33 (3.4 %) patients had biochemical failure based on the phoenix definition of Nadir + 2. Not including impotence, acute toxicity greater than or equal to Grade 2 was seen in 115 patients (102 GU and 13 GI) and 193 patients had late toxicity greater than or equal to Grade 2 (155 GU and 38 GI). 563 patients received hormone therapy prior to or concurrent with the radiation. Conclusions: This is the largest series reporting on the outcome of combination brachytherpay implant and external beam radiation in the treatment of prostate cancer. Combination treatment using brachytherapy and external beam radiation is well tolerated, with a low rate of biochemical failure and should be considered one of the treatment options for prostate cancer. No significant financial relationships to disclose.

Variations in treatment modality use for the definitive management of prostate cancer in the United States.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 174-174
Author(s):  
Jay P. Ciezki ◽  
Chandana A. Reddy ◽  
James Ulchaker ◽  
Kenneth Angermeier ◽  
Kevin L. Stephans ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Treatment Modality ◽  
External Beam Radiotherapy ◽  
The United States ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Choice Of Treatment ◽  
To Receive

174 Background: No prospective, randomized comparative efficacy trial exists to guide treatment of definitively managed prostate cancer patients. Despite this, treatment selection varies nationally and we attempt to assess these patterns of use. Methods: The SEER database was queried to identify cases of prostate cancer diagnosed between 1998-2008. The modalities identified were brachytherapy (brachy), combination of brachytherapy and external beam radiation (CombRT), external beam radiotherapy (EBRT), radical prostatectomy and external beam radiotherapy (RP+RT), and radical prostatectomy (RP). The number of cases by year, patient age and SEER region was computed. Results: There were 361,135 men in this analysis: 12.4% brachy, 6.8% CombRT, 27.5% EBRT, 3.1% RP+RT, and 50.3% RP. As expected, treatment modality varied by age with younger men more likely to receive RP and older man more likely to receive EBRT or brachy. There was some variation in choice of treatment modality over time: 6.6% for brachy; 4.2% for CombRT; 1.9% for EBRT; 2.0% for RP+RT; and 7.8% for RP. The variation in treatment modality by region was surprisingly wide (table): 14.4% for brachy; 25.5% for CombRT; 28.5% for EBRT; 3.8% for RP+RT; and 26.8% for RP. Conclusions: Choice of prostate cancer treatment modality varies by age, year of treatment, and most notably geographical region. Surprisingly the changes in reimbursement rates over the study period seem to have had minimal impact on choice of treatment modality. The regional variation implies that affiliations among healthcare providers significantly impact treatment. [Table: see text]

Predicting return of erectile function following external beam radiotherapy or brachytherapy for prostate cancer using EPIC-CP.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 87-87
Author(s):  
Stephen A. Mihalcik ◽  
Jonathan Chipman ◽  
Martin G. Sanda ◽  
Irving D. Kaplan ◽  
Catrina Crociani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Erectile Function ◽  
Goodness Of Fit ◽  
External Beam Radiotherapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Pearson Residuals ◽  
Patient Reported

87 Background: EPIC-CP (Expanded Prostate Cancer Index Composite for Clinical Practice) is a one page, 16-item questionnaire designed and validated to measure patient-reported health related quality of life in prostate cancer (PC) patients at the point of care in the clinical setting. We previously developed and externally validated models predictive of intact sexual function (i.e. achieving an erection firm enough for intercourse) at two years following external beam radiation (EBRT) or brachytherapy (BT) using EPIC-26, the parent tool from which EPIC-CP was derived. We aimed to enable the use of these models in clinical practice by recalibrating them for use with EPIC-CP. Methods: Using a previously described multicenter longitudinal cohort (PROST-QA), we identified 217 men treated with EBRT and 230 with BT with complete sexual domain and model covariate information. We used the established covariates predictive of functional erections in the EPIC-26-based models (baseline sexual score, neoadjuvant hormonal therapy, and baseline PSA for EBRT, and baseline sexual score, age, race, and BMI for BT) to recalibrate the multivariable logistic regression models for use with EPIC-CP. We examined Pearson residuals to determine goodness of fit and compared the individual predictions based on the revised models with those generated by the EPIC-26-based models. Results: The recalibrated EPIC-CP-based models demonstrated excellent discrimination (AUC 0.81 for EBRT, AUC 0.87 for BT). Odds ratio estimates for the EPIC-CP models changed by no more than 0.2 from their EPIC-26 counterparts, and remained statistically significant. EPIC-CP and EPIC-26-based predictions had good concordance: the mean ± SD difference in predicted probability between EPIC-26 and EPIC-CP models was 0.0 ± 0.08 in each treatment group. Predicted probabilities were within 15.4% and 15.8% for 95% of the subjects treated with EBRT and BT, respectively. Conclusions: EPIC-CP-based nomograms predicting erectile function two years after EBRT or BT are in good agreement with established EPIC-26-based tools and offer an easily applied and accurate prediction regarding a common and impactful side effect of PC treatment.

Health Outcomes After External-Beam Radiation Therapy for Clinically Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study

2001 ◽  
Vol 19 (9) ◽  
pp. 2517-2526 ◽  
Author(s):  
A. S. Hamilton ◽  
J. L. Stanford ◽  
F. D. Gilliland ◽  
P. C. Albertsen ◽  
R. A. Stephenson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Sexual Function ◽  
External Beam Radiotherapy ◽  
Bowel Function ◽  
Localized Prostate Cancer ◽  
External Beam Radiation ◽  
External Beam ◽  
Function Score ◽  
Urinary Function ◽  
Beam Radiation

PURPOSE: Studies reporting effects of radiotherapy for prostate cancer on sexual, bowel, and urinary function have been conducted primarily in referral centers or academic institutions. Effects of external-beam radiotherapy for prostate cancer among a population-based cohort were assessed. PATIENTS AND METHODS: The study population included 497 white, Hispanic, and African-American men with localized prostate cancer from six US cancer registries who were diagnosed between October 1, 1994, and October 31, 1995, and treated initially with external-beam radiotherapy. They were interviewed at regular intervals, and medical records were reviewed. Distributions of responses for bowel-, urinary-, and sexual-related functions at 6, 12, and 24 months after diagnosis and adjusted mean composite change scores for each domain were analyzed. RESULTS: Declines of 28.9% in the sexual function score and 5.4% in the bowel function score occurred by 24 months, whereas at this time, the urinary function score was relatively unchanged. A total of 43% of those who were potent before diagnosis became impotent after 24 months. More than two thirds of the men were satisfied with their treatment and would make the same decision again. CONCLUSION: Sexual function was the most adversely affected quality-of-life domain, with problems continuing to increase between 12 and 24 months. Bowel function problems increased at 6 months, with partial resolution observed by 24 months. Despite the side effects, satisfaction with therapy was high. These results are representative of men in community practice settings and may be of assistance to men and to clinicians when making treatment decisions.

scholarly journals Salvage Radical Prostatectomy after External Beam Radiation Therapy: A Systematic Review of Current Approaches

2015 ◽  
Vol 94 (4) ◽  
pp. 373-382 ◽  
Author(s):  
Deliu Victor Matei ◽  
Matteo Ferro ◽  
Barbara Alicja Jereczek-Fossa ◽  
Giuseppe Renne ◽  
Nicolae Crisan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Salvage Therapy ◽  
External Beam Radiotherapy ◽  
Local Treatment ◽  
Localized Prostate Cancer ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Selection Of

Background: Radical external beam radiotherapy (EBRT) is a standard treatment for prostate cancer patients. Despite this, the rate of intraprostatic relapses after primary EBRT is still not negligible. There is no consensus on the most appropriate management of these patients after EBRT failure. For these patients, local salvage therapy such as radical prostatectomy, cryotherapy, and brachytherapy may be indicated. Objective: The objectives of this review were to analyze the eligibility criteria for careful selection of appropriate patients and to evaluate the oncological results and complications for each method. Methods: A review of the literature was performed to identify studies of local salvage therapy for patients who had failed primary EBRT for localized prostate cancer. Results: Most studies demonstrated that local salvage therapy after EBRT may provide long-term local control in appropriately selected patients, although toxicity is often significant. Conclusions: Our results suggest that for localized prostate cancer recurrence after EBRT, the selection of a local treatment modality should be made on a patient-by-patient basis. An improvement in selection criteria and an integrated definition of biochemical failure for all salvage methods are required to determine which provides the best oncological outcome and least comorbidity.

Sign in / Sign up

Export Citation Format

Share Document